

National Institutes of Health**National Institute on Drug Abuse;
Notice of Meetings**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the National Institute on Drug Abuse (NIDA) advisory committee meetings.

These meetings will be open to the public as indicated below with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the contact person in advance of the meeting.

Ms. Camilla L. Holland, NIDA Committee Management Officer, National Institutes of Health, Parklawn Building, Room 10-42, 5600 Fishers Lane, Rockville, MD 20857, (301) 443-2755, will provide summaries of the meetings and rosters of committee members upon request. Substantive program information may be obtained from the contacts listed below.

Committee Name: National Advisory Council on Drug Abuse

Meeting Date: February 7-8, 1995

Place:

February 7, National Institutes of Health, Building 31, Conference Room 10, 9000 Rockville Pike, Bethesda, MD 20892

February 8, Parklawn Building, Conference, Room G, 5600 Fishers Lane, Rockville, MD 20857

Open: February 7, 1995, 9 a.m.-5 p.m.

Agenda: Administrative, legislative, and program development reports

Closed: February 8, 1995, 9 a.m. to adjournment

Agenda: Review and evaluation of grant applications

Contact: Eleanor C. Friedenber, Executive Secretary, Parklawn Building, Room 10-42, 5600 Fishers Lane, Rockville, MD 20857, Telephone (301) 443-2755

Committee Name: Drug Abuse Biomedical Research Review Committee

Meeting Date: February 13, 1995

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814

Open: February 13, 8:30 a.m. to 9:30 a.m.

Agenda: Presentation by the Director, NIDA

Contact: Gamil Debbas, Ph.D., Scientific Review Administrator, Parklawn Building, Room 10-42, 5600 Fishers Lane, Rockville, MD 20857, Telephone (301) 443-2620

Committee Name: Biochemistry Research Subcommittee, Drug Abuse Biomedical Research Review Committee

Meeting Date: February 13-15, 1995

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814

Closed: 12 Noon

Agenda: Review and evaluation of grant applications

Contact: Rita Liu, Ph.D., Scientific Review Administrator, Parklawn Building, Room 10-42, 5600 Fishers Lane, Rockville, MD 20857, Telephone (301) 443-2620

Committee Name: Pharmacology I Research Subcommittee, Drug Abuse Biomedical Research Review Committee

Meeting Date: February 13-15, 1995

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814

Closed: 9:30 a.m.

Agenda: Review and evaluation of grant applications

Contact: Syed Husain, Ph.D., Scientific Review Administrator, Parklawn Building, Room 10-42, 5600 Fishers Lane, Rockville, MD 20857, Telephone (301) 443-2620

Committee name: Pharmacology II Research Subcommittee, Drug Abuse Biomedical Research Review Committee

Meeting Date: February 13-15, 1995

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814

Closed: 9:30 a.m.

Agenda: Review and evaluation of grant applications

Contact: Gamil Debbas, Ph.D., Scientific Review Administrator, Parklawn Building, Room 10-42, 5600 Fishers Lane, Rockville, MD 20857, Telephone (301) 443-2620.

Committee name: Drug Abuse Epidemiology and Prevention Research Review Committee

Meeting Date: February 14-15, 1995

Place: Ramada Inn, Rockville, 1775 Rockville Pike, Rockville, MD 20852

Open: February 14, 8:30 a.m. to 9:30 a.m.

Agenda: Presentation by the Director, NIDA

Closed: 9:30 a.m.

Agenda: Review and evaluation of grant applications

Contact: Raquel Crider, Ph.D., Scientific Review Administrator, Parklawn Building, Room 10-22, 5600 Fishers Lane, Rockville, MD 20857, Telephone (301) 443-9042.

These meetings will be closed in accordance with provisions set forth in

secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Program Numbers: 93.277, Drug Abuse Research Scientist Development and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs)

Dated: January 25, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-2374 Filed 1-31-95; 8:45 am]

BILLING CODE 4140-01-M

Social Security Administration**Commission on Childhood Disability**

AGENCY: Social Security Administration, HHS.

ACTION: Notice of public meeting.

SUMMARY: This notice announces the initial organizational meeting of the Commission on Childhood Disability (the Commission).

DATES: Friday, February 3, 1995, 1 p.m. to 4 p.m.

ADDRESSES: Sheraton City Center, 1143 New Hampshire Ave. NW., Washington, DC, Potomac Room.

FOR FURTHER INFORMATION CONTACT: Elaine Fultz, Commission Staff Director, (202) 690-7409.

SUPPLEMENTARY INFORMATION:**I. Purpose**

Title II, Section 202 of the Social Security Independence and Program Improvements Act of 1994 (P.L. 103-296) requires the Secretary of Health and Human Services to appoint a Commission on the Evaluation of Disability in Children for the purpose of evaluating the effects of the current definition of disability under title XVI of the Social Security Act (42 U.S. Code 1381 et seq) as such definition applies to eligibility of children to receive SSI benefits, the appropriateness of such definition, and advantages and disadvantages of any alternative definitions. The study will also consider